| Particulars (Rupees in Crores.) | Sept-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 |
|---|---|---|---|---|---|
Gross Sales | 78.73 | 72.59 | 65.09 | 59.51 | 66.75 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 78.73 | 72.59 | 65.09 | 59.51 | 66.75 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.85 | 0.91 | 0.82 | 0.6 | 1.31 |
Total Income | 79.58 | 73.49 | 65.91 | 60.11 | 68.07 |
Total Expenditure | 54.61 | 48.84 | 45.91 | 41.26 | 43.56 |
PBIDT | 24.97 | 24.66 | 20 | 18.86 | 24.51 |
Interest | 2.78 | 2.7 | 2.06 | 1.98 | 2.13 |
PBDT | 22.19 | 21.95 | 17.94 | 16.87 | 22.38 |
Depreciation | 10.14 | 9.48 | 8.73 | 8.83 | 8.75 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 3.1 | 2.88 | 1.47 | 2.15 | 3.58 |
Deferred Tax | 0.12 | 0.42 | 0.57 | -0.09 | -0.1 |
Reported Profit After Tax | 8.83 | 9.18 | 7.17 | 5.98 | 10.16 |
Minority Interest After NP | -0.16 | -0.22 | -0.22 | -0.17 | -0.19 |
Net Profit after Minority Interest | 8.99 | 9.4 | 7.39 | 6.15 | 10.34 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 8.99 | 9.4 | 7.39 | 6.15 | 10.34 |
EPS (Unit Curr.) | 1.73 | 1.8 | 1.42 | 1.18 | 1.94 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 10.42 | 10.41 | 10.41 | 10.42 | 8.63 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.71 | 33.97 | 30.72 | 31.69 | 36.71 |
PBDTM(%) | 28.18 | 30.23 | 27.56 | 28.34 | 33.52 |
PATM(%) | 11.21 | 12.64 | 11.01 | 10.04 | 15.22 |
Suraksha Diagnostics specializes in medical consultancy services, hoping to attract investors in the rising healthcare sector
The anchor book, available to institutional investors, will open a day earlier, on November 28, 2024.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.